M. Sc, CEO.
Andreas Gerward
Andreas has during the last 10 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.
andreas.gerward@stayble.se +46 (0)730 808 397The shareholders of Stayble Therapeutics AB, corporate ID no. 559024-8372, are hereby invited to the Annual General Meeting on 5 June 2025 at 1:00 p.m. at the company’s office at Lennart Torstenssonsgatan 8 in Gothenburg. Registration for the Annual General Meeting will begin at 12:30 p.m.
For more information (in Swedish) see
https://staybletherapeutics.com/sv/investerare/bolagsstyrning/arsstamma-2024/
